var data={"title":"Dexrazoxane: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dexrazoxane: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6003?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dexrazoxane-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dexrazoxane: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dexrazoxane-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dexrazoxane: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158533\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Totect;</li>\n      <li>Zinecard</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158534\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zinecard</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158556\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Antidote, Extravasation;</li>\n      <li>\n        Chemoprotective Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158535\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of doxorubicin cardiomyopathy:</b> IV: A 10:1 ratio of dexrazoxane:doxorubicin (dexrazoxane 500 mg/m<sup>2</sup>:doxorubicin 50 mg/m<sup>2</sup>). <b>Note:</b> Cardiac monitoring should continue during dexrazoxane therapy; doxorubicin/dexrazoxane should be discontinued in patients who develop a decline in LVEF or clinical CHF.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of anthracycline extravasation:</b> IV: 1000 mg/m<sup>2</sup> on days 1 and 2 (maximum dose: 2,000 mg/day), followed by 500 mg/m<sup>2</sup> on day 3 (maximum dose: 1,000 mg/day); begin treatment as soon as possible, within 6 hours of extravasation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9645632\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dexrazoxane-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dexrazoxane: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Prevention of doxorubicin cardiomyopathy associated with acute lymphoblastic leukemia treatment (high-risk patients; off-label use):</b> IV: A 10:1 ratio of dexrazoxane:doxorubicin (eg, dexrazoxane 300 mg/m<sup>2</sup>:doxorubicin 30 mg/m<sup>2</sup>) was used in patients with high-risk acute lymphoblastic leukemia; dexrazoxane is administered immediately prior to the doxorubicin dose (Lipshultz 2010; Moghrabi 2007; Silverman 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158536\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F730126\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Renal function may be estimated using the Cockcroft-Gault formula.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;40 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;40 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention of cardiomyopathy: Reduce dose to 50% of the usual dose, using a 5:1 dexrazoxane:doxorubicin ratio (eg, dexrazoxane 250 mg/m<sup>2</sup>:doxorubicin 50 mg/m<sup>2</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anthracycline extravasation: Reduce dose to 50% of the usual dose; monitor for signs of hematologic toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158537\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of cardiomyopathy:</b> Since doxorubicin dosage is reduced in hyperbilirubinemia, a proportional reduction in dexrazoxane dosage is recommended (maintain a 10:1 ratio of dexrazoxane:doxorubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthracycline extravasation:</b> Use in patients with hepatic impairment is not recommended (has not been studied); monitor liver function tests prior to each dose in patients with known hepatic function disorders; hepatic dysfunction (transaminase and bilirubin elevations) may occur, particularly with doses above 1,000 mg/m<sup>2</sup>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158514\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Totect: 500 mg (1 ea) [pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zinecard: 250 mg (1 ea); 500 mg (1 ea) [pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea); 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea); 500 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158500\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158517\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Prevention of doxorubicin cardiomyopathy: Administer doxorubicin within 30 minutes after completion of the dexrazoxane infusion (do not administer doxorubicin before dexrazoxane).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zinecard: Administer by rapid drip infusion over 15 minutes; do <b>not</b> administer by IV push</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dexrazoxane generic formulation (Mylan): Administer by slow IV push or rapid drip infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of anthracycline extravasation: Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Administer dexrazoxane IV over 1 to 2 hours; begin infusion as soon as possible, within 6 hours of extravasation. Day 2 and 3 doses should be administered at approximately the same time (&plusmn; 3 hours) as the dose on day 1. Infusion solution should be at room temperature prior to administration. Infuse in a large vein in an area remote from the extravasation. For IV administration only; not for local infiltration into extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days; withhold cooling beginning at least 15 minutes before dexrazoxane infusion and continue withholding cooling during infusion (P&eacute;rez Fidalgo 2012). Do not use DMSO in combination with dexrazoxane; may lessen efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130973\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) if compounding. Double gloving and a gown are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158515\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of cardiomyopathy associated with doxorubicin (Zinecard, generic products):</b> To reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m<sup>2</sup> and will benefit from continuing doxorubicin therapy to maintain tumor control. Not recommended for use with initial  doxorubicin therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation of anthracyclines (Totect):</b> Treatment of extravasation resulting from intravenous anthracycline chemotherapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475040\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cardioprotectant for doxorubicin in malignancies other than breast cancer; Cardioprotectant for epirubicin in advanced breast cancer; Cardioprotectant for doxorubicin in acute lymphoblastic leukemia (ALL) treatment (children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158563\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zinecard may be confused with Gemzar</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158507\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Most adverse reactions are thought to be attributed to chemotherapy, except for increased myelosuppression, pain at injection site, and phlebitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prevention of doxorubicin cardiomyopathy</b> (reactions listed are those which were greater in the dexrazoxane arm in a comparison of chemotherapy plus dexrazoxane vs chemotherapy alone):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Cardiovascular: Phlebitis (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Central nervous system: Fatigue (61%), neurotoxicity (17%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Erythema (5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Bone marrow depression, granulocytopenia, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (23%), sepsis (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Pain at injection site pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (34%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Postmarketing, and/or case reports: Metastases (including acute myeloid leukemia, myelodysplastic syndrome)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Anthracycline extravasation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Cardiovascular:  Peripheral edema (10%), localized phlebitis (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Central nervous system: Fatigue (13%), dizziness (11%), depression (8%), headache (6%), insomnia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Dermatologic: Alopecia (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Endocrine &amp; metabolic: Hypercalcemia (7%), hyponatremia (6%), increased lactate dehydrogenase (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Gastrointestinal: Nausea (43%), vomiting (19%), diarrhea (11%), abdominal pain (6%), constipation (6%), anorexia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Hematologic &amp; oncologic: Decreased white blood cell count (73%; grade 3: 25%; grade 4: 20%), decreased neutrophils (61%; grade 3: 22%; grade 4: 24%), decreased hemoglobin (43%; grade 3: 3%), anemia (6%), febrile neutropenia (3%), neutropenia (3%), leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Hepatic: Increased serum AST (28%), increased serum ALT (22%),  increased serum bilirubin (11%), increased serum alkaline phosphatase (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Infection: Postoperative infection (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Local: Pain at injection site (16%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Renal: Increased serum creatinine (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Respiratory: Dyspnea (8%), pneumonia (6%), cough (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Miscellaneous: Fever (21%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158520\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinecard: Use with chemotherapy regimens that do not contain an anthracycline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Known hypersensitivity to dexrazoxane or any component of the formulation; use as a chemotherapeutic agent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Totect: There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158504\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Dexrazoxane may cause mild myelosuppression (leukopenia, neutropenia, and thrombocytopenia); myelosuppression may be additive with concurrently administered chemotherapeutic agents. When used for management of anthracycline extravasation (with cytotoxic chemotherapy), the nadir has occurred at days 10 to 12. Neutropenic fever has been reported when used with cytotoxic chemotherapy for management of anthracycline extravasation. Monitor complete blood cell count.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardioprotection: Dexrazoxane does not eliminate the potential for anthracycline-induced cardiac toxicity; carefully monitor cardiac function (left ventricular ejection fraction [LVEF]) prior to and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including anaphylactic reactions, angioedema, skin reactions, bronchospasm, respiratory distress, hypotension, and loss of consciousness have been reported; consider permanent discontinuation in patients with severe hypersensitivity reactions. Use with caution. Carefully consider prior to use in patients with a previous allergy to dexrazoxane products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been reported in pediatric patients and some adult patients receiving dexrazoxane in combination with chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor response: Dexrazoxane may interfere with the antitumor effect of chemotherapy when given concurrently with fluorouracil, doxorubicin, and cyclophosphamide (FAC).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Due to dosage adjustments for doxorubicin in hepatic impairment, when used for prevention of cardiomyopathy, a proportional dose reduction in dexrazoxane is recommended to maintain the dosage ratio of 10:1. For anthracycline extravasation, monitor liver function tests prior to each dose; hepatic dysfunction (manifested as transaminase and bilirubin elevations) may occur, particularly with doses above 1,000 mg/m<sup>2</sup>; use in patients with hepatic impairment is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal dysfunction (clearance is reduced); dosage adjustment required for CrCl &lt;40 mL/minute. Monitor for signs of hematologic toxicity in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration (extravasation): For IV administration; <b>not</b> for local infiltration into extravasation site. Do not use DMSO in patients receiving dexrazoxane for anthracycline extravasation; may diminish dexrazoxane efficacy. Dexrazoxane is not effective against the effects of vesicants other than anthracyclines; if other vesicants (eg, vinca alkaloids, mitomycin) were also infused through the same extravasated IV access, consider extravasation management for those agents as well.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration sequence (cardioprotection): When used for the prevention of cardiomyopathy, doxorubicin should be administered within 30 minutes after completion of the dexrazoxane infusion (do not administer doxorubicin before dexrazoxane).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299160\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219749\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9338&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethyl Sulfoxide: May diminish the therapeutic effect of Dexrazoxane.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): Dexrazoxane may diminish the therapeutic effect of DOXOrubicin (Conventional).  Management: Do not administer dexrazoxane for cardioprotection at the time of doxorubicin initiation.  This recommendation does not apply to the use of dexrazoxane for other indications (e.g., extravasation), or to the use of dexrazoxane later in treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158510\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158523\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies using doses less than the equivalent human dose (based on BSA). Based on the mechanism of action and findings in animal reproduction studies, dexrazoxane may cause fetal harm if administered during pregnancy. Females of reproductive potential should use highly effective contraception to prevent pregnancy during treatment and for 6 months after the last dexrazoxane dose. Males with female partners of reproductive potential should use effective contraception during therapy and for 3 months after the last dexrazoxane dose. Dexrazoxane may impair fertility in males of reproductive potential (it is not known if these effects are reversible).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158524\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dexrazoxane is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, for Totect, breastfeeding is not recommended during treatment and for 2 weeks following the last dexrazoxane dose; for Zinecard, a decision should be made to discontinue breastfeeding or to discontinue dexrazoxane, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158512\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (frequent); liver function tests prior to each dose (in patients with known liver function disorders); serum creatinine; cardiac function (repeat monitoring at 400 mg/m<sup>2</sup>, 500 mg/m<sup>2</sup> and with every 50 mg/m<sup>2</sup> of doxorubicin thereafter). Monitor site of extravasation (including after treatment and until resolution). Monitor for signs of hematologic toxicity in patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158503\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Dexrazoxane is a derivative of ethylenediaminetetraacetic acid (EDTA); a potent intracellular chelating agent. As a cardioprotectant, dexrazoxane appears to be converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated oxygen free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. In the management of anthracycline extravasation, dexrazoxane may act by reversibly inhibiting topoisomerase II, protecting tissue from anthracycline cytotoxicity, thereby decreasing tissue damage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158519\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes to heart, liver, and kidneys; V<sub>d</sub>: Children: 0.96 L/kg; Adults: 22 to 25 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hydrolyzed by dihydropyrimidine aminohydrolase and dihydroorotase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2.1 to 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (42%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323101\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Dexrazoxane Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $329.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $658.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Totect Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $573.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zinecard Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $281.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $563.72</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158525\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ao Nuo Xian (CN);</li>\n      <li>Cardioxane (AR, AT, BR, CL, CO, CR, CZ, DK, DO, EC, EG, ES, FI, FR, GB, GT, HN, HU, IL, IT, KR, LB, MX, NI, NL, PA, PE, PL, PY, SI, SV, UY, VE);</li>\n      <li>Cyrdanax (AT);</li>\n      <li>Cyrdanex (RO);</li>\n      <li>Dexarazoxane Martian (AR);</li>\n      <li>Dexrazoxane Chiron (AR);</li>\n      <li>Savene (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FR, GB, GR, HR, IE, IT, JP, LT, MT, NL, NO, PL, PT, RO, RU, SE, SI, SK, TR);</li>\n      <li>Totect (BM)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Barry EV, Vrooman LM, Dahlberg SE, et al, &ldquo;Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane,&rdquo; <i>J Clin Oncol</i>, 2008, 26(7):1106-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/18309945/pubmed\" target=\"_blank\" id=\"18309945\">18309945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brier ME, Gaylor SK, McGovren JP, et al. &ldquo;Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function,&rdquo; <i>J Clin Pharmacol</i>, 2011, 51(5):731-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/20484616/pubmed\" target=\"_blank\" id=\"20484616\">20484616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexrazoxane hydrochloride [prescribing information]. Rockford, IL: Mylan Institutional LLC; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19018081\"></a>Hensley ML, Hagerty KL, Kewalramani T, et al, &ldquo;American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiotherapy Protectants,&rdquo; <i>J Clin Oncol</i>, 2009, 27(1): 127-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/19018081/pubmed\" target=\"_blank\" id=\"19018081\">19018081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langer SW, Sehested M, and Jensen PB, &ldquo;Treatment of Anthracycline Extravasation With Dexrazoxane,&rdquo; <i>Clin Cancer Res</i>, 2000, 6(9):3680-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/10999761/pubmed\" target=\"_blank\" id=\"10999761\">10999761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langer SW, Thougaard AV, Sehested M, et al, &ldquo;Treatment of Anthracycline Extravasation in Mice With Dexrazoxane With or Without DMSO and Hydrocortisone,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2006, 57(1):125-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/16001176/pubmed\" target=\"_blank\" id=\"16001176\">16001176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipshultz SE, Miller TL, Scully RE, et al, &ldquo;Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes,&rdquo; <i>J Clin Oncol</i>, 2012, 30(10):1042-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/22370326/pubmed\" target=\"_blank\" id=\"22370326\">22370326</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20850381\"></a>Lipshultz SE, Scully RE, Lipsitz SR, et al, &ldquo;Assessment of Dexrazoxane as a Cardioprotectant In Doxorubicin-Treated Children With High-Risk Acute Lymphoblastic Leukaemia: Long-Term Follow-Up of a Prospective, Randomised, Multicentre Trial,&rdquo; <i>Lancet Oncol</i>, 2010, 11(10):950-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/20850381/pubmed\" target=\"_blank\" id=\"20850381\">20850381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopez M and Vici P, &ldquo;European Trials With Dexrazoxane in Amelioration of Doxorubicin and Epirubicin-Induced Cardiotoxicity,&rdquo; <i>Semin Oncol</i>, 1998, 25(4 Suppl 10):55-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/9768825/pubmed\" target=\"_blank\" id=\"9768825\">9768825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marty M, Espi&eacute; M, Llombart A, et al, &ldquo;Multicenter Randomized Phase III Study of the Cardioprotective Effect of Dexrazoxane (Cardioxane) in Advanced/Metastatic Breast Cancer Patients Treated With Anthracycline-Based Chemotherapy,&rdquo; <i>Ann Oncol</i>, 2006, 17(4):614-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/16423847/pubmed\" target=\"_blank\" id=\"16423847\">16423847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17003366\"></a>Moghrabi A, Levy DE, Asselin B, et al, &ldquo;Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for Children With Acute Lymphoblastic Leukemia,&rdquo; <i>Blood</i>, 2007, 109(3):896-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/17003366/pubmed\" target=\"_blank\" id=\"17003366\">17003366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mouridsen HT, Langer SW, Buter J, et al, &ldquo;Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies,&rdquo; <i>Ann Oncol</i>, 2007, 18(3):546-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/17185744/pubmed\" target=\"_blank\" id=\"17185744\">17185744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12065567\"></a>Schuchter LM, Hensley ML, Meropol NJ, et al, &ldquo;2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology,&rdquo; <i>J Clin Oncol</i>, 2002, 20(12):2895-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/12065567 /pubmed\" target=\"_blank\" id=\"12065567 \">12065567 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sehested M, et al, &ldquo;Dexrazoxane for Protection Against Cardiotoxic Effects of Anthracyclines,&rdquo; <i>J Clin Oncol</i>, 1996, 14:2884.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seif AE, Walker DM, Li Y, et al, Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. <i>Pediatr Blood Cancer</i>. 2014;62(4):8704-8709.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/24668949/pubmed\" target=\"_blank\" id=\"24668949\">24668949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20016537\"></a>Silverman LB, Stevenson KE, O'Brien JE, et al, &ldquo;Long-Term Results of Dana-Farber Cancer Institute ALL Consortium Protocols for Children With Newly Diagnosed Acute Lymphoblastic Leukemia (1985-2000),&rdquo; <i>Leukemia</i>, 2010, 24(2):320-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/20016537/pubmed\" target=\"_blank\" id=\"20016537\">20016537</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tebbi CK, London WB, Friedman D, et al, &ldquo;Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease,&rdquo; <i>J Clin Oncol</i>, 2007, 25(5):493-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/17290056/pubmed\" target=\"_blank\" id=\"17290056\">17290056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tetef ML, Synold TW, Chow W, et al, &ldquo;Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane I Patients With Advanced Malignancies,&rdquo; <i>Clin Cancer Res</i>, 2001, 7(6):1569-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/11410492/pubmed\" target=\"_blank\" id=\"11410492\">11410492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Totect (dexrazoxane) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venturini M, Michelotti A, Del Mastro L, et al, &ldquo;Multicenter Randomized Controlled Clinical Trial to Evaluate Cardioprotection of Dexrazoxane versus No Cardioprotection in Women Receiving Epirubicin Chemotherapy for Advanced Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 1996, 14(12):3112-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/8955656/pubmed\" target=\"_blank\" id=\"8955656\">8955656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vrooman LM, Neuberg DS, Stevenson KE, et al, &ldquo;The Low Incidence of Secondary Acute Myelogenous Leukaemia in Children and Adolescents Treated With Dexrazoxane for Acute Lymphoblastic Leukaemia: A Report From the Dana-Farber Cancer Institute ALL Consortium,&rdquo; <i>Eur J Cancer</i>, 2011, 47(9):1373-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/21514146/pubmed\" target=\"_blank\" id=\"21514146\">21514146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiseman LR and Spencer CM, &ldquo;Dexrazoxane. A Review of Its Use as a Cardioprotective Agent in Patients Receiving Anthracycline-Based Chemotherapy,&rdquo; <i>Drugs</i>, 1998. 56(3):385-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/9777314/pubmed\" target=\"_blank\" id=\"9777314\">9777314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang YP, Myers AL, Trinh VA, et al, Physical and chemical stability of reconstituted and diluted dexrazoxane infusion solutions. <i>J Oncol Pharm Pract</i>. 2014;20(1):58-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexrazoxane-drug-information/abstract-text/23676513/pubmed\" target=\"_blank\" id=\"23676513\">23676513</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zinecard (dexrazoxane) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Company; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zinecard (dexrazoxane) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; March 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9338 Version 139.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158533\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F158534\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F158556\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F158535\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9645632\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F158536\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F730126\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F158537\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158514\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F158500\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F158517\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130973\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F158515\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475040\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F158563\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F158507\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158520\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158504\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299160\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219749\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158510\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F158523\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F158524\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F158512\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158503\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F158519\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323101\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F158525\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9338|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dexrazoxane-patient-drug-information\" class=\"drug drug_patient\">Dexrazoxane: Patient drug information</a></li><li><a href=\"topic.htm?path=dexrazoxane-pediatric-drug-information\" class=\"drug drug_pediatric\">Dexrazoxane: Pediatric drug information</a></li></ul></div></div>","javascript":null}